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data for further pharmacokinetic and in vivo metabolism 
studies.
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Introduction
Modern medicine is facing growing difficulties in treat-
ment of bacterial infections resulting from an increasing 
number of antibiotic-resistant bacterial strains. The cause 
of this problem is the excessive use or misuse of antibacte-
rial medicines not only in the treatment of human infec-
tions, but also in the food industry, veterinary medicine 
and agriculture. Therefore, the current standard treatment 
is limited to using of one type of drug against specific 
pathogens [1]. amoxicillin, 6-{[amino(4-hydroxyphenyl)
acetyl]amino}-3,3-dimethyl-7-oxo-4-thial-1-azabicy-
clo[3.2.0]heptanes-2-carboxylic acid, belongs to β-lactam 
antibiotics of penicillin group [2]. This antibiotic acts 
against gram-positive and gram-negative bacteria and is 
most effective against anaerobes [2–4]. amoxicillin shows 
bactericidal effect as it blocks the activity of enzymes 
involved in synthesis of the cell wall. Bacteria lacking a 
stiff cell wall are more easily degraded under the influence 
of autolytic enzymes [5]. The antibiotic is used to treat 
certain bacterial infections such as gonorrhea, bronchitis, 
infections of the skin or soft tissue and infections of the 
upper and lower respiratory tract [2, 4].
Identification of the chemical structure of principal 
phase I and II metabolites is a basic step to assess the fate 
of biologically active compounds in an organism [6]. In 
vitro incubation of the drug with human liver subcellular 
Abstract amoxicillin (aMOX) metabolism in human 
liver microsomes was studied in vitro using liquid chro-
matography–mass spectrometry (lC/MS). amoxicillin 
was incubated with human liver microsomes along with 
naDPH, and the reaction mixture was analyzed by lC/
MS to obtain the specific metabolic profile of the stud-
ied antibiotic drug. Positive electrospray ionization was 
employed as the ionization source. an aCE C18-column 
(4.6 mm × 150 mm, 3 μm) was implemented with ace-
tonitrile and water (+0.1 % formic acid) in isocratic mode 
as the mobile phase at the flow 0.4 ml min−1. The chemi-
cal structures of metabolites were proposed on the basis of 
the accurate mass measurement of the protonated molecule 
as well as their main product. Six phase I and one phase II 
metabolites were detected and structurally described. The 
metabolism of aMOX occurred via oxidation, hydroxyla-
tion and oxidative deamination, as well as through combi-
nation of these reactions. Compound M7, with glucuronic 
acid was also observed as phase II metabolite. neither sul-
fate nor glutathione conjugates were detected. This study 
presents novel information about the chemical structure 
of the potential aMOX metabolites and provides vital 
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fractions (e.g., microsomes or the S9 fraction, etc.) is a 
simple and cost-effective method to acquire initial data 
regarding its metabolism (biotransformation) [7]. Drug 
metabolism and pharmacokinetic properties of new chemi-
cal entities are extensively investigated at various stages of 
drug discovery and development. In particular, drug metab-
olism is important in that it reveals the pharmacological 
activity and toxicological implications of a drug to ensure 
that it can be used safely in humans. Based on in vitro 
metabolism profiles, in vivo metabolism studies are further 
conducted through the advanced preclinical and phase I/II 
clinical trials [8–12].
High-performance liquid chromatography coupled with 
mass spectrometry represents one of the progressive ana-
lytical tools to study drug metabolism [13]. nowadays, 
mass spectrometers offer high resolution, sensitivity and 
accurate mass measurement for both precursor and product 
ions. Therefore, such instrumentation is capable of acquir-
ing data necessary for structure identification of unknown 
analytes (metabolites) within short time period and is a 
state-of-the-art technique for drug metabolism studies 
[14]. Determination of antibiotic drugs (and their potential 
metabolites) in complex matrices such as aqueous solu-
tions or physiological fluids (plasma, whole blood) requires 
appropriate isolation and preconcentration methods. In 
qualitative analyses and laboratory practice in life chem-
istry (bioanalytics, clinical analysis or medicine), the right 
selection of susceptible and reproducible methods support-
ing final determination and validation is essential [13, 14].
In this study, we applied lC/MS to identify phase I 
and phase II metabolites of aMOX as a model compound 
detected after in vitro incubation of the studied drug with 
human liver microsomes fraction. To the best of our knowl-
edge, no detailed information regarding the structure of 
aMOX metabolites via in vitro studies has been published. 
Transformations were investigated with HlM and in the 
presence of naDPH-P450 oxidoreductase. The results 
obtained will allow prediction of metabolic pathways of 
aMOX in patients differing in the level of cytochrome 
P450 isoenzymes and, in turn, can probably be helpful in 




amoxicillin (aMOX) was supplied by Sigma-aldrich 
(Schnelldorf, germany). Human liver microsomes (HlM), 
glucose-6-phosphate, β-naDP+, glucose-6-phosphate dehy-
drogenase and uridine 5′-diphosphoglucuronic acid triam-
monium salt (UDPga) were obtained from Sigma-aldrich 
(Schnelldorf, germany). Other chemicals of analytical qual-
ity (acetonitrile, formic acid) were purchased from Merck 
(Darmstadt, germany). Water was obtained by means of 
Milli-Q rg apparatus by Millipore (Millipore Intertech, Bed-
ford, Ma, USa) in our laboratory.
Phase I In Vitro Incubation
The drug incubation (aMOX, 1–25 μm) with HlM was 
performed in 100 mM phosphate buffer (PB), pH 7.4, 
at 37 °C for 90 min in a final reaction mixture volume of 
200 μl. The reaction was initiated by the addition of an 
naDPH-generating system containing 0.8 mM β-naDP+, 
10 mM glucose-6-phosphate and 1 unit of glucose-6-phos-
phate dehydrogenase to the reaction mixture. The blank 
samples were of the same composition as the test samples, 
but they did not contain aMOX. The omitted component 
in the control samples was replaced by an appropriate 
amount of PB to maintain a constant total sample volume. 
all samples were incubated at 37 °C for 1.5 h and shaken 
(120 rpm) during the incubation. The reaction was termi-
nated with 50 μl of ice-cold aCn, and the samples were 
stored at −20 °C. Thereafter, all samples were centrifuged 
(15,000g); then 180 μl of the supernatant was diluted with 
220 μl of water, filtered through a 0.22 μm filter and 
stored at −80 °C until analyzed. all samples were prepared 
in triplicate.
Phase II In Vitro Incubation
glucuronidation was studied by incubation of the model 
drug with HlM. The test and blank samples were prepared 
analogously to phase I metabolism samples, the exception 
being that 10 μl of PB contained the UDPga (50 mM) 
co-factor which mediated the relevant reaction. all samples 
were incubated and treated as described above.
Instrumentation
The HPlC 1100 (agilent, Waldbronn, germany) was 
used as the chromatographic system. It consisted of qua-
ternary pump (g 1310a), degasser and an automatic sam-
ple injection (g 1313a). The chromatographic separation 
was performed on aCE C18 (150 mm × 4.6 mm i.d., 5 μm 
particle, 300 Å) column with acetonitrile (+0.1 % formic 
acid) and water (+0.1 % formic acid) (65:35, v/v) mobile 
phase at the flow rate of 0.4 ml min−1. The column tem-
perature was 21 °C and the injection volume was 15 μl. 
The chromatographic run time was kept under than 6 min. 
additionally, the chromatographic system was coupled to 
the agilent 6410 Triple Quad mass spectrometer (agilent, 
Waldbronn, germany) equipped with an electrospray ion-
ization (ESI) interface operated in positive ion mode and 
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with the following operation parameters: gas temperature, 
325 °C; gas flow rate, 7.5 l min−1; nebulizer gas pressure, 
40 psi; and capillary voltage, 3,500 V. nitrogen was used in 
the ion source and the collision cell. Full-scan MS and then 
quadrupole precursor ion selection MS/MS in both positive 
mode was recorded within the mass range of m/z 50–600. 
additionally, ion acquisition was accomplished in multiple 
reaction monitoring (MrM) mode for quantification. agi-
lent Mass Hunter software version B.04.01 was used for 
data acquisition, instrument control and data analysis. For 
sample evaporation and centrifugation, a labconco Cen-
triVap Dna concentrator (Kansas City, USa) was used. 
Water was purified with a Milli-Q Purification System 
(Millipore, Bedford, Ma, USa).
Preparation of Stock and Standard Solutions
The working standard drug solutions, based on the thera-
peutic concentrations, were prepared by diluting the stock 
solution of amoxicillin (125 μg ml−1) to a proper vol-
ume. The stock solutions were diluted to make working 
standard solutions in the range from 1 to 50 μg ml−1. The 
plasma samples were stored at −20 °C. Before use, the 
plasma was thawed at room temperature and centrifuged at 
2,500g for 5 min. The spiked human liver microsome sam-
ples were prepared so as to reach final concentrations of 
1–50 μg ml−1.
Calibration and Validation
The method was validated under optimized conditions. 
Each calibration curve was the compilation of points cov-
ering from 1 to 50 μg ml−1. We used calibration curves 
prepared in triplicate by spiking human blank plasma to 
obtain the relevant concentration of aMOX. The accuracy 
was presented as the ratio of the determined and nomi-
nal values of the relevant drug concentrations and multi-
plied by 100 %. In addition, the precision was defined as 
the percentage of standard deviation of the relevant val-
ues divided by the average of mean values. The limit of 
detection (lOD = 3 × SDxy/b, where SDxy is the standard 
deviation and b is the slope) and the limit of quantification 
(lOQ = 10 × SDxy/b) were calculated with the acceptable 
precision and accuracy as defined by Konieczka [15]. The 
recoveries were determined by comparison of the peak 
areas after HPlC measurements of the spiked samples after 
respective sample preparation with the direct injection of 
standard solutions of equal concentrations. logically, lin-
earity was examined by analyzing blank plasma samples 
(n = 3) fortified with standard solutions of drugs at the 
same concentrations. The concentration range was obtained 
with the regression curve (y = ax + b) and correlation coef-
ficient (R2). The analytical procedure was fully validated 
according to the appropriate guidelines of the american 
Food and Drug administration [16]. Each point was the 
average of three injections with the injection volume of 
15 μl. Integrated peak areas of the selected quantification 
MrM transitions were used to build the standard curves. 
The standard curves were fitted using weighted least square 
regression analysis (1/χ) utilizing the Quanlynx function 
based on the signal-to-noise of 3:1 and 10:1, respectively. 
System control, data acquisition and interpretation were 
performed with the agilent Mass Hunter (Version 0.0100) 
software including the Qualitative package (for chroma-
tographic and spectral interpretation) and the Quantitative 
software (for quantitative information generation). Calibra-
tion curves were set up with the Mass Hunter Quantitative 
program using non-weighted least squares regression.
Data analysis
lC/MS data of the test and blank samples were compared 
both manually and using relevant software. Post-acquisition 
analyses were performed using Mass Hunter Metabolite ID 
(version 01.01) program (agilent, Waldbronn, germany), 
which employs an extensive list of potential biotransfor-
mation reaction (e.g., hydroxylation), in combination with 
the elemental compositions of the substrate molecules, to 
generate a series of extracted ion chromatograms (XICs). 
These XICs are compared between the control and sam-
ple to eliminate those chromatographic peaks in the sam-
ple that also appear in the control. Data mining algorithm 
“molecular feature extraction” was applied to extract com-
pounds. additionally, compound mass spectra were gener-
ated. The identification was based on accurate mass meas-
urements of precursor and product ions, considering the 
chemical structure of the parent compound and the general 
principles of metabolism as well.
Results and Discussion
ESI–MSn and lC–ESI/MS Studies for Mass Fragmentation 
Pattern of amoxicillin
Two-stage mass spectra (MS3) of amoxicillin were 
recorded to outline its mass fragmentation pattern for 
assisting the characterization of the fragmentation prod-
ucts (Fig. 1). The drug was detected at m/z 366 [M+H]+ 
(parent ion) and m/z 388 [M+na]+ (na-adduct ion) in 
the MS1 spectrum corresponding to its molecular mass of 
365 Da. The fragments of m/z 233 and 305 were observed 
both in MS2 and MS3 spectra. It indicated that they were 
stabilized probably by the cyclization leading to delo-
calization of the positive charge and hence became stable 
against further fragmentation. Fragmentation of the parent 
1030 M. Szultka et al.
1 3
ion in MS1 produced the heaviest ion (the one with the 
greatest m/z value), m/z 160, which was formed by the loss 
of 206 Da from m/z 366. The loss of 158 Da from the ion 
at m/z 366 may have led to fragment at m/z 208. The m/z 
160 was formed in the greatest abundance and thus was 
targeted as the precursor ion to generate the MS2 spectrum 
that showed product ion at m/z 114. It was suggested that 
the m/z 114 was formed by the loss of 46 Da from m/z 160. 
On the basis of the mass and second-highest abundance of 
the product ion, the m/z 349, corresponding to the loss of 
nH3, was used as the precursor ion for another MS3 study. 
It mainly fragmented to the product ions of m/z 305, 233, 
189, 136 and 70. The m/z 136 could have been formed by 
the loss of 213 Da.
The detection of ions by HPlC/ESI/MS/MS made it 
possible to determine the proposed fragmentation pathway 
of aMOX, as displayed in Fig. 2. Figure 2 presents the fol-
lowing fragmentation sequence: the loss of 205 Da with 
the formation of the ion at m/z 366; the loss of 47 Da with 
the formation of the ion at m/z 161; the loss of C10H8n2O3 
before C11H11n2O5 from the ion at m/z 366 resulting in the 
ions at m/z 161 and 114, respectively.
In Vitro Metabolic Profiling
There are a large number of components in the HlM, many 
of which may elute during analysis at the same time as the 
target compounds. To solve this problem, we performed the 
tests using Mass Hunter Metabolite ID software, and peaks 
present in the analyte were evaluated with reference to 
control samples by comparing their retention times during 
post-acquisition analyses, MS spectra and peak areas.
Under the chromatographic conditions used herein, 
the parent drug, aMOX, was detected as [M+H] + at 
m/z = 366 the retention time of 5.93 min. The fragmenta-
tion behavior of the parent drug was studied to provide ini-
tial data for the interpretation of mass spectra of its metab-
olites. The protonated molecule of aMOX gave three main 
product ions in the MS/MS scan, as mentioned above.
The incubation of amoxicillin with human liver micro-
somes in the presence of naDPH generated 7 metabolite 
peaks (S/n ≥ 5), shown in Fig. 3. Extracted compound 
chromatograms and product ion spectra were derived and 
analyzed. When aMOX was incubated without micro-
somes, no metabolites were observed, indicating that all 
metabolites were generated in the presence of microsomal 
enzymes. analysis of the samples incubated with HlM 
revealed six phase I (M1–M6) metabolites and one phase 
II metabolite (M7). These potential metabolites were num-
bered M1–M7 according to their retention time. addition-
ally, MS/MS experiments using protonated molecules as 
the precursor ion were performed to confirm the suggested 
structures of the product ions formed.
The MH+ ions of the metabolites in the HlM sam-
ples were identified by full-scan MS detection (Fig. 3; 
Table 1). The metabolite M1 was observed at m/z = 382, 
indicating hydroxylation of the aromatic moiety; M2, at 
m/z = 379, indicating oxidative deamination of –nH2 
group; M3–M5, at m/z = 382, 380 and 396, respectively, 
indicating oxidation of aliphatic chain; M6, at m/z = 322 
indicating decarboxylation. The obtained metabolites at 
m/z = 379 and 322 are associated with the additional loss 
of nH2 and CO2, respectively. additionally, one glucuro-
nide was detected after incubation of the parent drug with 
HlM using UDPga as a co-factor. Metabolite M7 with 
[M+H]+ at m/z = 542 corresponds to the conjugation of 
the parent drug with glucuronic acid. Indeed, the MS/MS 
spectrum showed the typical neutral loss of glucuronic acid 
(Δ −176 Da) and the identical product ion at m/z = 208 
identical with that of the parent drug. neither sulfate nor 
glutathione conjugates were detected. The postulated met-
abolic pathway for all metabolites is presented in Fig. 4. 
Table 1 shows the retention time, experimental mass m/z, 
Fig. 1  Two-stage mass spectra data of amoxicillin
1031Identification of In Vitro Metabolites by LC–ESI/MS
1 3
Fig. 2  Proposed fragmentation 
pathway of amoxicillin
Fig. 3  representative extracted 
ion chromatogram of amoxicil-
lin and its metabolites produced 
following the incubation with 
human liver microsomes
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elemental composition and characteristic metabolic reac-
tion in the MS/MS stage of the target metabolite.
The characteristic molecular ion of M1 (retention time 
2.34 min) was obviously at m/z = 382 which was 16 Da 
lower than the protonated ion of aMOX, indicating that it 
was formed through hydroxylation of amoxicillin in aro-
matic moiety. nevertheless, the software applied did not 
indicate the exact hydroxylation site. The components in 
the HlM extracts were identified and confirmed accord-
ing to the mass spectrometric fragmentation mechanism 
through the means of MS/MS characteristic fragment 
ions. Figures 4 and 5 show MS/MS spectra of compounds 
M1–M7. The compound fragments easily yielded dominant 
characteristic ions, which indicates the presence of the rel-
evant groups in the molecule.
Finally, the principal metabolic reactions for amoxicil-
lin detected in vitro were oxidation, hydroxylation, oxida-
tive deamination and conjugation with glucuronic acid. 
Spectra interpretation for compounds M1–M7 was carried 
out to identify suspect biotransformation products, and all 
fragmentations were analyzed thoroughly to draw general 
conclusions on fragmentation characteristics of potential 
metabolites, with the aim to help in and facilitate the iden-
tification of novel compounds for personalized antibiotic 
therapy. The metabolites detected after incubation with 
HlM were not found in the control samples. all phase I 
Table 1  The retention times, 
mass characteristics and 
elemental composition of the 
[M+H]+ of aMOX and the 
metabolites, M1–M7





aMOX 5.93 366 C16H20n3O5S –
M1 2.34 382 C16H20n3O6S Hydroxylation
M2 2.52 379 C17H19n2O7S Oxidative deamination
M3 2.76 382 C16H20n3O6S Oxidation of aliphatic chain
M4 2.94 380 C16H18n3O6S Oxidation of aliphatic chain
M5 3.48 396 C16H20n3O7S Oxidation of aliphatic chain
M6 3.98 322 C15H19n3O3S Decarboxylation
M7 4.49 542 C25H28n3O11S glucuronidation
Fig. 4  Postulated metabolic pathways of amoxicillin in human liver microsomes
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metabolic reactions found in this study are typically cata-
lyzed by the P450 superfamily of enzymes [17].
Method Validation
The multiple reaction monitoring mode was used to moni-
tor the precursor ion and the corresponding product ion, 
which could reduce interference and enhance selectivity. 
amoxicillin was detected at m/z 366 [M+H]+. Quantifi-
cation was performed using MrM of the m/z 366 → 160 
transition. The knowledge of such transition can be of 
interest to confirm the quantitative results obtained for 
the measurements of the target analyte in complex matrix 
mainly in the presence of interfering compounds.
nine concentrations (1, 3, 5, 7, 10, 15, 20, 30 and 
50 μg ml−1) defined the calibration curves. The calibra-
tion curve for amoxicillin was linear over the concentra-
tion range 1–50 μg ml−1. Standard curve used in this 
study was determined using the following linear regres-
sion: y = ax + b (SDxy = 552, R2 = 0.999), where y is 
the peak area, a (10,627, SDa = 67) is the slope, x is the 
respective concentration and b (−1,480, SDb = 308) is the 
intercept. The limit of detection (lOD) and limit of quanti-
fication (lOQ) were found to be 0.031 and 0.093 μg ml−1, 
Fig. 5  The representative product ion spectra corresponding to the potential metabolites M1–M7 (a–g)
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respectively. relative standard deviation (rSD) was 
0.93 %.
Calibration curves of the human samples spiked with 
target compound was determined in the relevant con-
centration range. Obtained data with back calculated 
values, accuracy and precision are shown in Tables 2 
and 3. The analysis of aMOX using MrM function was 
highly selective with no interfering compounds. Specific-
ity was performed using six different lots of human liver 
microsomes.
Intra-assay and inter-assay accuracy and precision were 
assessed over three separate days by preparing a daily 
standard calibration curve along with 4 replicates of lQC, 
MQC, and HQC samples. Statistical analysis of the accu-
racy and precision is presented in Table 3. The intraday 
and interday %CV were ≤12.4 and ≤12.6 %, respectively. 
The intraday and interday %Bias was within ±4.4 and 
±10.7 %, respectively.
Stability of aMOX in biological samples was tested at 
three concentration levels (1, 7 and 15 μg ml−1) under dif-
ferent conditions. The results of stability tests for biologi-
cal samples: autosampler (accuracy ranging from −3.94 
to 2.82 % and precision <1.21 % for the analyzed drug), 
freeze and thaw (accuracy ranging from −3.28 to 2.41 % 
and precision <4.21 % for the analyzed drug), short term 
(accuracy ranging from −5.21 to 4.38 % and precision 
<2.11 % for the analyzed drug), and preliminary long term 
at two storage temperatures (accuracy ranging from −5.92 
to 4.35 % and precision <0.94 % for the analyzed drug). 
For each concentration level, there were acceptance criteria 
falling within the range 85–115 %. In addition, evaluated 
were the respective stability tests that confirmed the sta-
bility of amoxicillin in the stock and working solutions at 
1–4 °C after 1 month. The target compound was proven to 
be stable both in stock solution (at −4 °C) and in human 
samples (at −20 °C) after long-term storage (for 1 month). 
These data indicated the analyte was stable during sample 
preparation and chromatographic measurements.
Conclusions
a lC/MS method for the analysis of the amoxicillin as a 
model compound was developed and applied to obtain the 
first data regarding the chemical structures of its main phase 
I and phase II metabolites after incubation with human liver 
microsomes in vitro. The parent drug was incubated with 
human liver fractions to search for phase I metabolites. 
Thereafter, glucuronidation was also investigated. Elemen-
tal compositions of both the precursor and product ions 
were calculated based on mass measurements. Chemical 
structures of the metabolites detected were then proposed. 
Six phase I and one phase II metabolites were detected and 
structurally described. The metabolism of aMOX occurred 
via oxidation, hydroxylation and oxidative deamination, 
as well as the combination of these reactions. Compound 
M7, with glucuronic acid was also observed as phase II 
metabolite. neither sulfate nor glutathione conjugates were 
detected. Proposed analytical procedure was shown to be 
adequate for the intended pharmacokinetic applications, 
i.e., the incubations experiments with microsomes origi-
nating from liver samples from patients underwent anti-
bacterial therapy. additionally, although the total level of 
liver microsomal P450s does not vary considerably among 
humans, genetic polymorphism and susceptibility to induc-
tion of a given P450 isoenzyme result in interindividual 
variations in levels of P450 isoforms (CYPs) [18]. In this 
light, all data concerning selectivity in catalytic properties 
of various CYPs towards a potent drug are desirable [19]. 
Table 2  Intraday accuracy 
and precision of amoxicillin in 
human liver microsomes





amoxicillin (n = 10) 1 1.1 ± 0.3 108.3 6.83
3 3.3 ± 0.01 107.7 1.66
5 5.3 ± 0.7 105.5 6.25
7 6.9 ± 0.4 98.1 0.24
10 9.5 ± 0.4 94.8 3.10
15 15.2 ± 0.3 101.1 3.26
20 20.1 ± 0.4 100.4 2.44
30 28.9 ± 0.1 96.2 2.90
50 47.3 ± 0.6 94.4 2.76
Table 3  accuracy and precision results
nominal concentration 
(μg ml−1)
Intraday (n = 4) Interday (n = 3)
%Bias %CV %Bias %CV
lQC 1 −2.5 12.4 −10.7 12.6
MQC 20 −0.5 11.7 −5.0 7.9
HQC 50 −4.4 6.1 −6.9 5.6
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The above-discussed possibilities of selective metabolism 
of aMOX presumably dependent on the expression of 
P450 isoenzymes build up a background of individualized 
direct therapy with this drug, which is particularly critical 
in the case of antibiotic therapy.
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